Iron may be a factor in dementia

February 17, 2015 by Leigh Dayton, University of Technology, Sydney
Iron may be a factor in dementia
Dr Dominic Hare at work in his laboratory. Credit: George Ganio

Alzheimer's disease is no respecter of fame or fortune. Former US president Ronald Reagan had it. Legendary AC/DC guitarist Malcolm Young has been diagnosed. Hazel Hawke suffered until her death in 2013. And author and broadcaster Anne Deveson is experiencing the distressing progression of Alzheimer's, the most common form of dementia, a group of brain disorders affecting thinking and memory.

There is no way to spot Alzheimer's early, no effective treatment and no known cure. However, a neurochemist at the University of Technology, Sydney (UTS), Dr Dominic Hare, and his colleagues are homing in on a biomarker, or disease indicator, to help diagnosis.

Moreover, Dr Hare – who is also with the Florey Institute of Neuroscience and Mental Health in Melbourne and the Icahn School of Medicine at Mount Sinai in New York City – says the team's work promises to help reveal the cause of the baffling disorder.

"The disease develops so slowly and has so many effects on the body, being able to separate what's cause and what's effect is a big problem," he says. "If we can identify why the disease is happening, we could intervene to alleviate the symptoms and potentially halt the disease process."

At present, a diagnosis of Alzheimer's disease is made only after careful clinical consultation, and any diagnosis can be confirmed only by examining the brain after death.

However, Dr Hare and his co-workers are not looking in the brain for clues. They're looking in the blood. In a recent article in the US journal ACS Neuroscience, the group outlined its work with a potential biomarker and a possible causative culprit: .

"The body uses metals like copper, zinc and iron to facilitate biochemical reactions it wants. In the case of disease, these are reactions that are unwanted," Dr Hare says, adding that iron plays a very important role in the ageing process, and ageing is the key risk factor for Alzheimer's disease. One in four people over the age of 85 have dementia; 75 per cent of those have Alzheimer's.

Professor Perminder Sachdev, co-director of the Centre for Healthy Brain Ageing at the University of NSW, says metals have previously been linked to Alzheimer's but the findings were inconclusive.

"This study by Dr Hare and his colleagues is, therefore, of interest to researchers in the field," says Professor Sachdev, chief medical adviser to Alzheimer's Australia.

Specifically, Dr Hare's team is studying transferrin, a protein that helps ferry iron around the body. In the case of Alzheimer's, if transferrin falls down on the job iron may accumulate in the brain, where it contributes to the build-up of "plaques" and "tangles". Plaques impede the transmission of signals among brain cells and tangles kill them.

To track transferrin's activity, Dr Hare teamed up with Dr Blaine Roberts, head of the Metalloproteomics Laboratory at the Florey Institute. They designed the research using blood samples collected for the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).

The multi-disciplinary, multi-institutional project is one of world's largest studies of the biomarkers, cognitive characteristics and lifestyle factors implicated in Alzheimer's.

"The unique thing about AIBL is that it's following 1000 people through time," Dr Hare says. "That gives us statistical power." Participants provide blood samples and are tracked over 54 months.

Dr Hare, Dr Roberts and their colleagues used samples from 34 AIBL participants and 36 healthy participants. They employed specialised equipment to analyse samples: an inductively coupled plasma-mass spectrometer (ICP-MS), and a size exclusion chromatography-inductively coupled plasma-mass spectrometer (SEC-ICP-MS).

The results revealed, first, that compared to healthy volunteers, participants with Alzheimer's had lower levels of iron in their plasma, a condition linked with anaemia of unknown cause.

Intriguingly, results from the ICP-MS and SEC-ICP-MS tests, showed healthy and Alzheimer's participants had the same amount of transferrin in their blood but that the amount of iron carried by the transferrin was lower in Alzheimer's samples. The implication: transferrin isn't shuttling excess iron efficiently from the brain.

"The next step is to look at a copper-binding protein called ceruloplasmin that interacts with transferrin," says Dr Hare. "Putting all these pieces together will help find methods to maintain quality of life, possibly slowing or even halting the progress of the disease."

Explore further: Biotech company develops way to carry antibodies across blood-brain barrier to treat Alzheimer's

Related Stories

Biotech company develops way to carry antibodies across blood-brain barrier to treat Alzheimer's

November 6, 2014
(Medical Xpress)—A team of researches with the biotech firm Genentech Inc has found a way to carry an antibody across the blood-brain barrier using transferrin in a monkey. In their paper published in the journal Science ...

Uncovering the underlying causes of Parkinson's disease

April 3, 2014
(Medical Xpress)—A breakthrough investigation by UTS researchers into the underlying causes of Parkinson's disease has brought us a step closer to understanding how to manage the condition.

Research could lead to Alzheimer's drugs

February 6, 2015
New insights into how nerves cells in the brain maintain efficient communication with each other may help offset the effects of Alzheimer's disease.

Scientists much closer to developing screening test for early detection of Alzheimer's disease

May 1, 2013
They identified blood-based biological markers that are associated with the build up of a toxic protein in the brain which occurs years before symptoms appear and irreversible brain damage has occurred.

Eyes, ears and nose may aid Alzheimer's disease prevention and treatment

January 30, 2015
Detecting a decline in certain sensory functions may become the future of preventing Alzheimer's disease (AD), with research showing smell testing and retinal imaging to be strong predictors of dementia risk.

Neurogeneticists harness immune cells to clear Alzheimer's-associated plaques

February 5, 2015
New research from scientists at the Keck School of Medicine of the University of Southern California (USC) shows that the body's immune system may be able to clear the brain of toxic plaque build-up that is the hallmark of ...

Recommended for you

Study clarifies ApoE4's role in dementia

September 20, 2018
ApoE4, a protein linked to both Alzheimer's disease and a form of dementia caused by damage of blood vessels in the brain, increases the risk of cognitive impairment by reducing the number and responsiveness of blood vessels ...

Machine learning IDs markers to help predict Alzheimer's

September 19, 2018
Nearly 50 million people worldwide have Alzheimer's disease or another form of dementia. These irreversible brain disorders slowly cause memory loss and destroy thinking skills, eventually to such an extent that self-care ...

Discovery could explain failed clinical trials for Alzheimer's, and provide a solution

September 19, 2018
Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also identifies a clinically ...

Air pollution may be linked to heightened dementia risk

September 18, 2018
Air pollution may be linked to a heightened risk of developing dementia, finds a London-based observational study, published in the online journal BMJ Open. The associations found couldn't be explained by factors known to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

Study prevents cognitive decline in older blacks with memory loss

September 10, 2018
With nearly twice the rate of dementia as whites, blacks are at a higher risk for developing diseases like Alzheimer's, but there has been little research on how to reduce this racial health disparity. A new study in black ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Feb 17, 2015
When anyone is diagnosed with Alzheimers, the most important thing you can do is to be certain the diagnosis is accurate. I cared for people in their homes for fifteen years. The husband of one patient began asking me the same questions repeatedly. I usually accompanied them to doctor appointments, but this time they went alone. Bill was promptly diagnosed with early onset Alzheimers. When I came to their home, their eyes were swollen from crying. I told them not to panic. I phoned ACAM [American College of Alternative Medicine].]. We lived in Southern Oregon and was fortunate to find a doctor in Portland. This is a man who could think 'out of the box'. After talking to Bill for about five minutes, he told him that he was quite certain that he didn't have Alzheimers. He said that he could run lots of expensive time consuming tests, but with his permission, he would like to go with his 'gut feeling'. He prescribed LTryptophan and in three weeks, Bill was back to normal.
not rated yet Feb 18, 2015
deesund....I would like to ask you some questions if possible. The repeated questions is what I'm interested in and what about the conversation with the doctor made him feel it wasn't Alzheimer's. If you can post to this site again I will give you my email address. Please help.
Feb 23, 2015
This comment has been removed by a moderator.
not rated yet Feb 23, 2015
yvchawla...I'm so glad you cleared that up! For those of us wanting REAL help....we'll keep looking.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.